These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 32193547)

  • 1. Multiparametric MRI for early identification of therapeutic response in recurrent glioblastoma treated with immune checkpoint inhibitors.
    Song J; Kadaba P; Kravitz A; Hormigo A; Friedman J; Belani P; Hadjipanayis C; Ellingson BM; Nael K
    Neuro Oncol; 2020 Nov; 22(11):1658-1666. PubMed ID: 32193547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors.
    Hagiwara A; Oughourlian TC; Cho NS; Schlossman J; Wang C; Yao J; Raymond C; Everson R; Patel K; Mareninov S; Rodriguez FJ; Salamon N; Pope WB; Nghiemphu PL; Liau LM; Prins RM; Cloughesy TF; Ellingson BM
    Neuro Oncol; 2022 Jun; 24(6):1020-1028. PubMed ID: 34865129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative Evaluation of Diffusion and Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Differentiation Between Primary Central Nervous System Lymphoma and Glioblastoma.
    Lu S; Wang S; Gao Q; Zhou M; Li Y; Cao P; Hong X; Shi H
    J Comput Assist Tomogr; 2017; 41(6):898-903. PubMed ID: 28806317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Early Response to Anti-Angiogenic Therapy in Recurrent Glioblastoma: Amide Proton Transfer-weighted and Perfusion-weighted MRI compared with Diffusion-weighted MRI.
    Park JE; Kim HS; Park SY; Jung SC; Kim JH; Heo HY
    Radiology; 2020 May; 295(2):397-406. PubMed ID: 32154775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging biomarkers guided anti-angiogenic therapy for malignant gliomas.
    Kong Z; Yan C; Zhu R; Wang J; Wang Y; Wang Y; Wang R; Feng F; Ma W
    Neuroimage Clin; 2018; 20():51-60. PubMed ID: 30069427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiparametric MRI for Differentiation of Radiation Necrosis From Recurrent Tumor in Patients With Treated Glioblastoma.
    Nael K; Bauer AH; Hormigo A; Lemole M; Germano IM; Puig J; Stea B
    AJR Am J Roentgenol; 2018 Jan; 210(1):18-23. PubMed ID: 28952810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma.
    Thomas AA; Arevalo-Perez J; Kaley T; Lyo J; Peck KK; Shi W; Zhang Z; Young RJ
    J Neurooncol; 2015 Oct; 125(1):183-90. PubMed ID: 26275367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response Assessment in Neuro-Oncology criteria, contrast enhancement and perfusion MRI for assessing progression in glioblastoma.
    Tensaouti F; Khalifa J; Lusque A; Plas B; Lotterie JA; Berry I; Laprie A; Cohen-Jonathan Moyal E; Lubrano V
    Neuroradiology; 2017 Oct; 59(10):1013-1020. PubMed ID: 28842741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging--pilot study.
    Sawlani RN; Raizer J; Horowitz SW; Shin W; Grimm SA; Chandler JP; Levy R; Getch C; Carroll TJ
    Radiology; 2010 May; 255(2):622-8. PubMed ID: 20413772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentiation of solitary brain metastasis from glioblastoma multiforme: a predictive multiparametric approach using combined MR diffusion and perfusion.
    Bauer AH; Erly W; Moser FG; Maya M; Nael K
    Neuroradiology; 2015 Jul; 57(7):697-703. PubMed ID: 25845813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bidirectional Contrast agent leakage correction of dynamic susceptibility contrast (DSC)-MRI improves cerebral blood volume estimation and survival prediction in recurrent glioblastoma treated with bevacizumab.
    Leu K; Boxerman JL; Lai A; Nghiemphu PL; Pope WB; Cloughesy TF; Ellingson BM
    J Magn Reson Imaging; 2016 Nov; 44(5):1229-1237. PubMed ID: 26971534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of apparent diffusion coefficient in predicting the outcome of Gamma Knife-treated brain metastases prior to changes in tumor volume: a preliminary study.
    Goldman M; Boxerman JL; Rogg JM; Norén G
    J Neurosurg; 2006 Dec; 105 Suppl():175-82. PubMed ID: 18503353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of dynamic contrast perfusion MRI to predict early response to bevacizumab in newly diagnosed glioblastoma: results from ACRIN 6686 multicenter trial.
    Schmainda KM; Prah MA; Marques H; Kim E; Barboriak DP; Boxerman JL
    Neuro Oncol; 2021 Feb; 23(2):314-323. PubMed ID: 32678438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Demonstration of DCE-MRI as an early pharmacodynamic biomarker of response to VEGF Trap in glioblastoma.
    O'Neill AF; Qin L; Wen PY; de Groot JF; Van den Abbeele AD; Yap JT
    J Neurooncol; 2016 Dec; 130(3):495-503. PubMed ID: 27576699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiparametric imaging-based differentiation of lymphoma and glioblastoma: using T1-perfusion, diffusion, and susceptibility-weighted MRI.
    Saini J; Kumar Gupta P; Awasthi A; Pandey CM; Singh A; Patir R; Ahlawat S; Sadashiva N; Mahadevan A; Kumar Gupta R
    Clin Radiol; 2018 Nov; 73(11):986.e7-986.e15. PubMed ID: 30197047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interval Change in Diffusion and Perfusion MRI Parameters for the Assessment of Pseudoprogression in Cerebral Metastases Treated With Stereotactic Radiation.
    Knitter JR; Erly WK; Stea BD; Lemole GM; Germano IM; Doshi AH; Nael K
    AJR Am J Roentgenol; 2018 Jul; 211(1):168-175. PubMed ID: 29708785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of relative cerebral blood volume in patients with recurrent glioblastoma multiforme treated with bevacizumab.
    Stecco A; Amatuzzo P; Sponghini AP; Platini F; Quagliozzi M; Buemi F; Guenzi E; Carriero A
    J Neurosurg Sci; 2019 Aug; 63(4):394-401. PubMed ID: 27603407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.
    Schmainda KM; Zhang Z; Prah M; Snyder BS; Gilbert MR; Sorensen AG; Barboriak DP; Boxerman JL
    Neuro Oncol; 2015 Aug; 17(8):1148-56. PubMed ID: 25646027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognosis prediction of non-enhancing T2 high signal intensity lesions in glioblastoma patients after standard treatment: application of dynamic contrast-enhanced MR imaging.
    Kim R; Choi SH; Yun TJ; Lee ST; Park CK; Kim TM; Kim JH; Park SW; Sohn CH; Park SH; Kim IH
    Eur Radiol; 2017 Mar; 27(3):1176-1185. PubMed ID: 27357131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interobserver variability in the radiological assessment of magnetic resonance imaging (MRI) including perfusion MRI in glioblastoma multiforme.
    Kerkhof M; Hagenbeek RE; van der Kallen BF; Lycklama À Nijeholt GJ; Dirven L; Taphoorn MJ; Vos MJ
    Eur J Neurol; 2016 Oct; 23(10):1528-33. PubMed ID: 27424939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.